NEW YORK (GenomeWeb) – Minneapolis-based Bio-Techne, a provider of tools and bioactive reagents for research and clinical diagnostics, said today that it has closed on a strategic equity investment valued at $43 million in Astute Medical, which is marketing a biomarker-based diagnostic test for acute kidney injury.

Bio-Techne said that the deal has been structured to allow it to build a strategic foundation in diagnostics, and includes an option for it to further expand the relationship.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.